Fig. 5

Docetaxel suppressed glycolysis and tumor growth in vivo. Null mice bearing PC-3M cell tumors were administered a daily vehicle [control group; 5% (w/v) dextrose] or Docetaxle at 10 nM for 2 weeks (4 mice per group). A The body weight of indicated group was measured 3 day per time, B tumor volume was represented at indicated time, C the excised tumor images were presented. D HE staining was used to show the tumor morphological alterations. E Immunohistochemistry staining for Ki-67, HIF-1α and PFKP. Magnification 400 ×, the mean density of Ki-67, HIF-1α and PFKP were quantified and analyzed by two sample t test. Data represented the mean ± s.d. **P < 0.01, ***P < 0.001. F Western blotting was performed to detect the phosphorylation of Smad3 (Ser213) in indicated group, β-actin served as internal control. The intensity of band was quantified, data represented the mean ± s.d. of three independent experiments and analyzed by t test, **P < 0.01, ***P < 0.001